248 total views, 1 views today
Other scientific studies released at the official MDR-TB press conference at the 49th Union World Conference on Lung Health includes data from multiple countries showing impact of innovative MDR-TB treatment effort with Bedaquiline curing hundreds of cases of MDR-TB in Eastern Europe and Central Asia
A simple method for processing stool samples for Xpert MTB/RIF testing using minimal equipment has been announced at the 49th Union World Conference on Lung Health and could enable the identification of thousands of children with tuberculosis (TB) and multidrug-resistant TB (MDR-TB) disease – drastically reducing the numbers of children under five dying from TB.
Currently, an estimated 239,000 children die every year from tuberculosis (TB). Children with TB rarely die when they receive standard treatment for the disease, but 90 percent of children who die from TB worldwide went untreated.
Young children cannot spit up a sputum specimen and other methods are needed to get a sputum sample off them, which are complex, invasive, stressful and painful and often need the children to be hospitalised overnight (usually for the smallest children (< 5y) gastric aspiration is used, in which a tube is brought into the child’s stomach via his or her nose.)
Stool sampling has in recent times been under investigation but it has been widely considered that stool is a difficult sample, because it contains so many other bacteria and debris, and it is believed that the Mycobacterium tuberculosis bacilli are fully “encapsulated” by other materials in the sample, making it difficult to “free” the bacilli. It was previously believed that good quality DNA material could only be obtained from stool in multiple cleaning steps using sophisticated equipment.
A new simple method developed by researchers at the KNCV Tuberculosis Foundation involves mixing a sample of stool with a sample of the SR (Sample Reagent) buffer (which comes with every Xpert machine cartridge in bottles of 8 ml). This simple Xpert stool test was positive (showing TB) in all children who also had positive respiratory samples – there were no false negative stool samples. The work was done in collaboration with Ethiopian and Indonesian research institutes, and the respective national TB control programs.
The test also identifies resistance to rifampicin which is a marker for MDR-TB.
“No child should die from TB,” said José Luis Castro, Executive Director of The International Union Against Tuberculosis and Lung Diseases (The Union). “There is an urgent need to drastically step up investment in research and development that can deliver new and better diagnostic tools such as this stool test. Promising breakthroughs of this kind are needed if we are to make inroads into preventing illness and death from both active and MDR-TB.”
Kitty van Weezenbeek, Executive Director of the KNCV Tuberculosis Foundation which developed the method in collaboration with the National Tuberculosis Programs of Ethiopia and Indonesia, said: “If further testing confirms the preliminary findings in Indonesia and Ethiopia, the potential of this method is enormous and means that being able to diagnose TB and MDR-TB from stool would mean that we have a method in our hands that can diagnose TB at the lowest health care level and can bring testing to hundreds of thousands of people. In that way, children can now get a microbiologically confirmed TB diagnosis at primary health centres, where that is currently not possible.”
Currently, to obtain a sputum test, children are referred to specialised service providers, as testing is not possible at the community level.
Additionally, current stool processing methods use sophisticated centrifugation and filtration that are only available in referral laboratories, usually attached to referral hospitals.
Today’s press conference highlighted four abstracts (shown below) being presented at the 49th Union World Conference on Lung Health 2018. (Note: Press summaries are based on abstracts; final data presented at the conference may change).
Simple stool processing method for the diagnosis of pulmonary TB using GeneXpert
The diagnosis of pediatric pulmonary tuberculosis (pTB) is difficult and often relies on clinical signs and symptoms, as obtaining respiratory specimens for testing of young children is challenging. GeneXpert MTB/Rif can be applied on stool samples for diagnosing pTB, but until now, this method is not routinely implemented due to the complexity of the available processing methods.
Petra de Haass, Laboratory Advisor at the KNCV Tuberculosis Foundation in The Hague, The Netherlands, reported on a simple method for processing stool samples for Xpert MTB/RIF testing using minimal equipment. This method was tested in vitro using TB-negative stool samples from children in Ethiopia, and on stool samples from 36 children with presumptive pTB aged <15 years in a tertiary care hospital in Bandung, Indonesia. From these children, respiratory samples (RS) were also obtained by gastric aspiration for children aged 5 or below and by sputum induction for older children and tested with Xpert for comparison.
The in vitro tests showed the potential of the method; using a very simple method, omitting homogenization and filtration steps, reliable results were obtained and no significant inhibition of amplification, a critical step in the GeneXpert process, was observed.
The median age of the children with presumptive pTB was 17 months (interquartile range: 5.5-78 months). pTB was diagnosed among 6 of them (17%); 27/29 submitting stool and RS had an interpretable test result on both samples, the results being concordant in 24 (89%, 95% confidence interval: 71-98%). The three children with discordant results all had an MTB-positive result on stool only.
This groundbreaking work shows that a simple and low-cost method, using similar processing steps as are applied for sputum, can diagnose TB at any GeneXpert site using stool samples, and can even diagnose additional children. The method has the potential to make a bacteriological diagnosis of TB in children at the lowest levels of health care.
Source: The Union